1. Sodium phosphate was infused intravenously over approximately 2+ h and produced a mean linear rise in plasma phosphorus levels of 9.1 mg/100 ml. Twentyone infusions were performed in twelve control subjects and thirty-eight were carried out in thirty-two patients with disorders of calcium and phosphorus metabolism. threshold.
consistently lowered during this process and the exact fate of calcium removed from the blood is still uncertain. While some data (Philpot, 1958) have suggested that plasma calcium falls only in hypercalcaemic patients other observations (Hebert, Lemann, Petersen & Lennon, 1966) have suggested that the fall occurs in all subjects and is accomplished by generalized metastatic precipitation of hydroxyapatite. Evidence that the fall in plasma calcium level is related to the rise in plasma phosphorus (Thompson & Hiatt, 1957) and to the initial plasma calcium level (Hyde, Jones, McSwiney & Prunty, 1960 ) is scanty and requires confirmation.
The present study was undertaken to investigate more fully the hypocalcaemic effect of intravenous phosphate by comparing its extent in patients with a range of metabolic disorders including parathyroid dysfunction, osteoporosis, osteomalacia and Paget's disease. A further aim was to establish the relationships to the phosphorus increment, the initial plasma calcium level, and certain other indices of calcium and phosphorus metabolism. Evidence of possible renal damage due to phosphate administration was sought in a smaller series of more prolonged infusions.
SUBJECTS A N D M E T H O D S
Forty-four subjects were tested in the larger series of infusions on fifty-nine occasions. They were divided into six groups: (1) a control group consisting of twelve subjects (twenty-one tests) who were either healthy volunteers or had no evidence of disordered calcium and phosphorus metabolism (one patient had treated tropical sprue and one had sclerodactyly without evidence of systemic sclerosis) ; (2) nine patients with primary hyperparathyroidism subsequently proven at operation, of whom two had osteitis fibrosa; (3) eight patients (twelve tests) either with active osteomalacia or receiving long-term treatment for renal tubular defects including hereditary vitamin D resistant rickets, Wilson's disease, and adult-presenting hypophosphataemic osteomalacia; (4) four patients with hypoparathyroidism ; (5) three patients with idiopathic osteoporosis ; (6) a miscellaneous group of eight patients (ten tests) whose diagnoses are listed in Table 1 .
Infusions consisted of a 0.1 M solution of sodium phosphate buffered to pH 7.4 (Na2HP04. 2H20, 13.8 g; NaH,P04.2H20, 3.6 g, water to 1 1.) and were designed in the larger series of tests to produce a linear rise in plasma phosphorus levels with time. Using the Buchler Polystaltic pump (Buchler Instrument Co., Fort Lee, New Jersey, U.S.A.) the infusion rate was raised by a constant increment every 15 min and a linear rise in plasma phosphorus was obtained over a period of 2-3 h. Subjects were fasting throughout the test but were given ample water to drink to maintain a good urine flow. By plotting urine phosphorus excretion in six consecutive urine collections against plasma phosphorus levels during the procedure simultaneous determination was made of theoretical renal phosphorus threshold (TRPT) and glomerular filtration rate (GFR) (Stamp & Stacey, 1970) . Subjects received a total of 60-90 mmol phosphate depending roughly on their size and clinical condition. Calcium determinations were performed before and near the end of the infusion, and in some instances at intervals during the test. The mean infusion time to the final plasma calcium determination was 155 f 12 (SD) min in controls and 156 12 (SD) min in patients with disordered calcium metabolism.
A smaller series of five constant infusions of 10 h duration was performed in four patients with moderately severe hypercalcaemia. Three of these patients had primary hyperparathyroidism with osteitis fibrosa and one had bronchial carcinoma. Six urine collections were made at 2-hourly intervals beginning with a control period before the start of the infusion. Mid-point blood specimens were taken and plasma and urine were analysed for calcium, phosphorus, and renal clearances of endogenous creatinine and either [51Cr]EDTA or inulin. Urine specimens were also analysed for protein and cell excretion rates. After the initial fasting blood specimen patients ate and drank normally during the course of the infusion.
Calcium was determined on an Eppendorf flame photometer and phosphorus by the method of Gomorri (1942) phosphorus were performed in duplicate or triplicate to obtain accuracy to the nearest 0.05 mg/100 ml. Plasma calcium values were corrected for plasma specific gravity, where indicated, by using a factor of plus or minus 0.25 mg/100 ml for each third decimal place below or above a plasma SG of 1-027 respectively (Dent & Watson, 1968) . ['lCr]EDTA was counted in a Packard Auto-gamma spectrometer, inulin was estimated by Dawborn's (1 966) modification of Heyrovsky's (1956) indolylacetic acid method, and standard laboratory techniques were used for all other determinations. Student's t-test and the correlation coefficient r were used for statistical analysis.
R E S U L T S Short-term infusions
Hypocalcaemic symptoms in the form of transient tingling in the extremities were noted in about six patients but only two of them (both receiving vitamin D for osteomalacia) were in any way distressed and required calcium injection for relief.
Analysis of the linear rise in plasma phosphorus levels showed very similar mean increments in the control group and in the patients, 8.922.1 (SD) mg/100 ml and 9.3+2*7 (SD) mg/100 ml, respectively ( t = 0.58). Plasma specific gravity fell slightly during the infusions due to haemodilution, equivalent to a mean plasma calcium correction of minus 0.3 mg/100 ml in both groups.
The relationship between change in plasma phosphorus and change in plasma calcium is illustrated in Fig. 1 for all but eight subjects (see Table 1 ). The regression line of calcium change on phosphorus change is also shown. In all subjects the correlation coefficient (r) of 0.39 was highly significant (t = 3.28, P<0.0025).
Correlation between the initial plasma calcium level and the fall in plasma calcium was also determined for all subjects and found to be highly significant, whether corrected or uncorrected for SG. Thus for corrected plasma calcium changes, r = 0.34 (t = 2.73, P<0.005). Fig. 2 illustrates the slightly different relationship between initial calcium levels and the fall in plasma calcium per mg rise in plasma phosphorus. Fig. 1 illustrates convincingly the relatively marked hypocalcaemic effect of phosphate administration not only in patients with primary hyperparathyroidism who were hypercalcaemic (range 10.5-13.3 mg/100 ml), but also in patients with osteoporosis who were virtually normocalcaemic (range 9-7-10.7 mg/100 ml) and in patients with osteomalacia some of whom were hypocalcaemic (range 7.5-10.8 mg/100 ml). For example the mean corrected initial plasma calcium levels in the control and osteomalacic groups were 9.9 f 0.3 (SD) and 9.5 k 0.9 (SD) mg/100 ml respectively. Patients with hypopai.athyroidism who were hypocalcaemic (range 6.6-8.4 mg/100 ml) were by contrast as 'resistant' as normal subjects.
The effect of phosphate was expressed as the ratio of change in plasma calcium (mg per 100 ml)/rise in plasma phosphorus (mg/lOO ml) which occurred during the infusion period.
The mean 'phosphate effects' in the control and osteomalacic groups were -0-043 f 0.041 (SD) and -0.1 19k0.047 (SD) respectively and this difference was highly significant (Pt0.001). Similar differences from normal in patients with hyperparathyroidism and with osteoporosis are apparent on inspection of Fig. 1 . The two patients with osteitis fibrosa were among the three most affected hyperparathyroid patients. The increased 'phosphate effect' in eight individual patients is shown in Table 1 . Two of these (nos. 1 and 2) had chronic renal failure arbitrarily defined as GFR less than 40 ml/min. Two (nos. 3 and 4) were hypercalcaemic from causes other than hyperparathyroidism. There was one case of nutritional rickets in an adolescent (no. 6), one case of idiopathic juvenile osteoporosis (no. 7). One unusual case (no. 8) showed a combination of nutritional osteomalacia and tertiary hyperparathyroidism; she was studied following the removal of a parathyroid adenoma when she showed a 'hungry bones stage' despite having no radiological evidence of osteitis fibrosa. The most pronounced effect in the whole series was seen in a patient with Paget's disease (no. 5). Her plasma calcium and phosphorus levels and TRPT were entirely normal, but radiologically her bone disease was gross and the plasma alkaline phosphatase level was 204 K.A.U.
The relationships between the effects of phosphate and both the initial plasma phosphorus levels and the closely related theoretical renal phosphorus threshold were also studied. The correlation coefficients between the 'phosphate effect' and fasting plasma phosphorus and between the 'phosphate effect' and TRPT (illustrated in Fig. 2) were very similar and both were highly significant (r = 0.464 and 0.470, t = 3-81 and 3.88 respectively; P<0.0005). Ten-hour infusions Changes in plasma calcium and phosphorus levels during five constant 10 h phosphate infusions are shown in Fig. 3 . Table 2 shows the results of determinations of creatinine clearance together with the urinary excretion of calcium, protein, and leucocytes during the control period and the changes in each measurement during successive urine collections. Measurements of inulin or [51Cr]EDTA clearance were only obtained after the control period and are not represented; no notable changes in either were seen during the course of the infusions. The extent of any fall in urinary calcium excretion appeared directly related to the fall in plasma calcium levels. No notable changes were seen in urine protein or cell excretion except for the increase in urine cell excretion rate in the fourth infusion period which just reached a level of significance (0.02 < P < 0.05).
D I S C U S S I O N
The fate of calcium removed from the blood by phosphate administration and the mechanisms by which this occurs have been the subject of considerable controversy and are still imperfectly understood. Albright, Bauer, Claflin & Cockrill (1932) and Dent (1962) warned of the possibilities of soft tissue calcification following phosphate ingestion in patients with hypercalcaemia. Gersh (1938) described transient reticulo-endothelial uptake of particulate calcium salts following intravenous phosphate administration to animals. Goldsmith & Ingbar (1 966) found extraskeletal calcification at autopsy in patients who had received phosphate (in one case along a vein from which extravasation of an infusion had occurred) and in some patients Hebert et al. (1966) found radiological evidence of calcification in the veins into which phosphate was infused. Finally we have noted the rapid appearance of prominent calcified subcutaneous masses at injection sites following the intravenous administration of concentrated (2% phosphorus) phosphate solutions in a patient terminally ill with inoperable hyperparathyroidism. It is perhaps thus established that metastatic calcium precipitation may occur under certain conditions. Hebert et al. (1966) found that serum calcium concentration fell in direct proportion to the magnitude by which the hydroxyapatite (CaHPO,) solubility product was exceeded during phosphate infusion, and concluded that simple physico-chemical precipitation of CaHPO, could adequately explain the mechanism by which serum calcium fell in all subjects. Their data conflicted with those of Philpot (1958) who could not demonstrate an effect in normal subjects using only orally administered phosphate, and have been challenged by Kahil et al. (1967) on the basis of observations that the plasma calcium nadir may persist after phosphorus levels have returned to normal.
The present findings have confirmed the tendency of phosphate administration to lower plasma calcium in all subjects. They have furthermore confirmed the unsupported statements that decline in plasma calcium is directly proportional both to the plasma phosphorus increment (Thompson & Hiatt, 1957) and to the initial height of plasma calcium (Hyde et al., 1960) . They are thus far consistent with the data of Hebert et al. (1966) described above. However the present study has clearly shown in addition that metabolic factors may be important in determining the extent of the fall in plasma calcium, in contradiction to the conclusions of the latter workers. The effect of phosphate was thus greater in certain groups of patients than in normal subjects or patients with hypoparathyroidism, who appeared relatively resistant, and the possible reasons must be considered. Not only were patients with hypercalcaemia (whether due to hyperparathyroidism, vitamin D intoxication, sarcoidosis, or the milk-alkali syndrome) more sensitive, but the effect was also more marked in patients with rickets or osteomalacia, osteoporosis, chronic renal failure and (especially) Paget's disease. Of the three patients with hyperparathyroidism in whom the effect of phosphate was most marked two were those with osteitis fibrosa. Increased bone resorption and new bone formation is a feature of secondary hyperparathyroidism in both osteomalacia and chronic renal failure as well as of Paget's disease, while increased resorption alone is found in osteoporosis.
It is thus possible to relate an increase in some unknown aspect of metabolic activity within bone to the increased effect of phosphate seen in all these conditions. Such activity may determine a partially selective deposition of calcium salts in bone in preference to purely generalized metastatic precipitation. Talmage, Toft & Davis (1 960) have shown that calcium precipitation in bone may occur when calcium is given to hyperphosphataemic nephrectomized rats. Treatment with oral phosphate alone is known to enhance calcification in bone in some forms of hypophosphataemic osteomalacia (Nagant de Deuxchaisnes & Krane, 1967), and has been reported to improve the calcium balance in patients with hyperparathyroidism (Dimich, Rothschild, Fulmer, Freed & Laird Meyers, 1969) . It is also relevant that a patient with inoperable hyperparathyroidism and osteitis fibrosa described by Dent (1962) showed first radiological healing of osteitis fibrosa with phosphate treatment given over 5 years without the appearance of metastatic calcification or of deterioration in renal function. Since that report this patient went on in 1965-66 to develop marked subcutaneous calcification, which resolved on stopping treatment. It recurred in 1969 after further continuous phosphate treatment, and has remitted a second time on again stopping this therapy. Her renal function has deteriorated only slowly throughout this whole period of 13 years.
All these findings may nevertheless be partially reconciled with the work of Hebert et al. (1966) . There has long been evidence for the intravascular formation of colloidal calcium phosphate under certain conditions (McLean & Hinrichs, 1938) . There is no good reason why this physico-chemical process should not occur in both normal subjects and patients with metabolic bone disease; it may only be the removal of such a colloidal solution which may be slow in normal subjects, thus producing relatively little change in total plasma calcium levels. Kahil et al. (1967) have also pointed out that extracellular fluid, while not normally saturated with Ca and HP04 ions, is supersaturated in respect to bone crystals, and thus in the vicinity of bone these ions are likely to be precipitated from fluid to solid phases. A colloidal complex might conceivably behave similarly. Eisenberg (1 970) has suggested that non-crystalline calcium phosphate might be deposited on bone surfaces as an unlikely alternative to soft tissues.
Most of the infusions in the present study were given in such a way as to produce a linear rise in plasma phosphorus levels over a roughly constant period of time. It thus appeared reasonable to represent the effect of phosphate in terms of the ratio of plasma calcium fall (in mg/100 ml)/plasma phosphorus increment (mg/lOO ml). The highly significant inverse proportion of this phosphate effect to both resting plasma phosphorus levels and theoretical renal phosphorus threshold (Stamp & Stacey, 1970) presumably reflects the relationship in the preponderance of patients with either primary or secondary hyperparathyroidism. Certain criticisms can however be levelled at the present experimental conditions. While the mean length of infusions in controls and patients were very similar, variation occurring within the series was dictated by the need for timed urine collections in order to determine TRPT. It was also not possible to control the total amount of phosphate infused, which varied between 60 and 90 mmol, as this would have given very wide fluctuations in the plasma phosphorus increments depending on renal function and body size in different subjects. In general however patients who showed marked effects had received smaller total amounts of phosphate than healthy controls. Finally in subjects whose calcium levels were followed at intervals throughout the infusion the rate of fall in some became more marked towards the end of the infusion. Urine calcium determinations during some short-term infusions suggested that calcium excretion tended to remain most constant in subjects whose plasma levels fell the least (Stamp & Lopez de Novales, unpublished).
The beneficial plasma calcium-lowering effect of phosphate has been confirmed during longer constant infusions in patients with moderately severe hypercalcaemia. In these patients also, the fall in urine calcium excretion was related to the fall in plasma calcium levels. Acute renal failure, associated with hypotension, has been reported following phosphate infusions in severely ill patients (Shackney & Hasson, 1967) . Evidence of renal damage was thus sought during 10 h phosphate infusions by serial determinations of glomerular filtration, urine protein and leucocyte excretion rates. There was a fairly wide scatter in all measurements but a significantly elevated cell excretion rate was noted by the sixth to eighth hours. The return of calcium levels toward pre-infusion values within 14 h after the infusions suggested that calcium phosphate deposited thus acutely either on bone surfaces or in soft tissues was still in a form which could easily be returned to the circulation.
The data presented here appear to strengthen the rationale of phosphate treatment in many cases of hypercalcaemia, as well as providing some slender support for phosphate supplements in other forms of metabolic bone disease such as osteoporosis and osteomalacia. There are nevertheless other forms of therapy which remain the treatment of choice in the great majority of hypercalcaemic illness. They include surgery in primary hyperparathyroidism, dietary calcium restriction in the milk-alkali syndrome, and corticosteroid therapy in vitamin D intoxication, sarcoidosis, and some malignant states.
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